Literature DB >> 35775166

Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.

Dinah V Parums1.   

Abstract

On 26 November 2021, the World Health Organization (WHO) identified the B.1.1.529 variant, or Omicron variant, as the fifth variant of concern (VOC) of SARS-CoV-2. The B.1.1.529 Omicron variant of SARS-CoV-2 includes five lineages, BA.1, BA.2, BA.3, BA.4. and BA.5. During the past six months, several identified sublineages of B.1.1.529 have rapidly spread globally. Although the lineages BA.1 and BA.2 initially predominated, BA.4, BA.5, and sublineage BA.2.12.1 are now dominant in Europe and the USA. On 12 May 2022, the European Centre for Disease Prevention and Control (ECDC) reclassified BA.4 and BA.5 from variants of interest (VOI) to variants of concern (VOC). BA.2.12.1, BA.4, and BA.5 have shown higher transmissibility and increased neutralization evasion compared with BA.2 when tested against plasma from patients with triple-vaccination and following infection with BA.1. On 7 June 2022, the World Health Organization (WHO) added a new category to its SARS-CoV-2 variant tracking system, the VOC Lineages Under Monitoring (VOC-LUM), which aims to inform global public health authorities of the VOC lineages and sublineages that may require prioritized attention and monitoring. This Editorial aims to present an update on the lineages and sublineages of the Omicron variant of SARS-CoV-2 and the VOC-LUM initiative from the WHO.

Entities:  

Mesh:

Year:  2022        PMID: 35775166      PMCID: PMC9254723          DOI: 10.12659/MSM.937676

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


On 26 November 2021, the World Health Organization (WHO) identified the B.1.1.529 variant, or Omicron variant, as the fifth variant of concern (VOC) of SARS-CoV-2 [1]. This designation followed the advice from the WHO Technical Advisory Group on Virus Evolution (TAG-VE) [1]. The designation of SARS-CoV-2 VOCS aimed to prioritize global disease monitoring, assist research, and inform global responses to the COVID-19 pandemic [1]. There were early concerns about this variant because of its rapid spread and the large number of viral mutations [1,2]. The B.1.1.529 Omicron variant of SARS-CoV-2 includes five lineages, BA.1, BA.2, BA.3, BA.4. and BA.5 (Table 1) [3]. The WHO currently decides on the degree of threat to populations from Omicron based on four criteria: viral transmissibility; how well prior infection and vaccines protect against transmission, infection, disease severity, and mortality; how virulent the variant is when compared with other variants; and how populations follow public health and social measures in response to the presence of the virus [3]. Based on the currently available evidence, the Omicron variant of SARS-CoV-2 has greater transmissibility and more rapid spread in the community, with increased incidence than other variants previously identified in the COVID-19 pandemic [1,3,4]. As of 20 June 2022, both the UK and the USA reported almost 1.2 million cases of infection with the Omicron or B.1.1.529 variant [5]. During the past six months, several identified sublineages of B.1.1.529 have rapidly spread globally (Tables 1, 2) [1,2]. Although infection with the B.1.1.529 variant, or Omicron variant, has a lower risk of severe disease and death than previous SARS-CoV-2 variants, the very high levels of transmission resulted in significant increases in hospitalization, leading to overwhelming demands on global healthcare systems [2,4]
Table 1

The five (Pango) lineages of the B.1.1.529 or Omicron variant of SARS-CoV-2 include BA.1, BA.2, BA.3, BA.4, and BA.5.

OMICRON LINEAGEGEOGRAPHIC REGION OF FIRST DETECTIONDATE FIRST DETECTEDDATE OF DESIGNATIONWHO STATUS
B.1.1.529SOUTH AFRICA24 NOVEMBER 2021DESIGNATED AS A VOC ON 26 NOV 2021VOC
BA.1*SOUTH AFRICAJANUARY 2022RE-DESIGNATED AS A VOC ON 22 FEB 2022VOC
BA.2*SOUTH AFRICAJANUARY 2022RE-DESIGNATED AS A VOC ON 22 FEB 2022VOC
BA.3SOUTH AFRICAJANUARY 2022NON-DESIGNATED – DETECTED WORLDWIDE BUT WITH FEW CASESNON-DESIGNATED
BA.4*SOUTH AFRICAJANUARY 2022DESIGNATED AS A VOC-LUM ON 7 JUNE 2022VOC-LUM
BA.5*SOUTH AFRICAJANUARY 2022DESIGNATED AS A VOC-LUM ON 7 JUNE 2022VOC-LUM

The WHO recommends that these descendant lineages of B.1.1.529 should be monitored as distinct lineages by public health authorities with comparative assessments of their viral characteristics.

VOC-LUM – variant of concern lineage under monitoring.

Adapted from: World Health Organization (WHO). SARS-CoV-2 Variants. 7 June 2022 [

Table 2

The Omicron lineages included in the World Health Organization (WHO) variants of concern lineages under monitoring (VOC-LUM), as of 7 June 2022.

PANGO LINEAGE DESIGNATIONRELATIONSHIP TO THE OMICRON VOCGEOGRAPHIC REGION AND DATE FIRST DETECTED
BA.4*SISTER LINEAGE OF BA.1 AND BA.2JAN 2022; SOUTH AFRICA
BA.5*SISTER LINEAGE OF BA.1 AND BA.2JAN 2022; SOUTH AFRICA
BA.2.12.1SUBLINEAGE OF BA.2DEC 2021; USA
BA.2.9.1SUBLINEAGE OF BA.2FEB 2022; MULTIPLE COUNTRIES
BA.2.11SUBLINEAGE OF BA.2MARCH 2022; MULTIPLE COUNTRIES
BA.2.13SUBLINEAGE OF BA.2FEB 2022; MULTIPLE COUNTRIES

On 12 May, 2022, the European Centre for Disease Prevention and Control (ECDC) reclassified sublineages BA.4 and BA.5 from variants of interest (VOI) to variants of concern (VOC) [6].

Adapted from: World Health Organization (WHO). SARS-CoV-2 Variants. 7 June 2022 [9].

As of 20 June 2022, the United Kingdom and the USA reported almost 1.2 million cases of infection with the Omicron or B.1.1.529 variant [5]. During the past six months, several identified sublineages of B.1.1.529 have rapidly spread globally. The initial lineages identified included BA.1 and BA.2. However, BA.4, BA.5, and sublineage BA.2.12.1 are now dominant in Europe and the USA [5]. On 12 May 2022, the European Centre for Disease Prevention and Control (ECDC) reclassified BA.4 and BA.5 from variants of interest (VOI) to variants of concern (VOC) [6]. There have been increasing concerns that previous infection with SARS-CoV-2 and vaccination using vaccines developed before these variants emerged may be ineffective [5,6]. Recent population and laboratory studies support the concerns regarding the potential threat of the new SARS-CoV-2 Omicron lineages and sublineages [7,8]. On 17 June 2022, in the journal Nature, Cai and colleagues reported that BA.2.12.1, BA.4, and BA.5 showed higher transmissibility than BA.2 [7]. Structural comparisons of the spike (S) protein showed that BA.2.12.1 and BA.4/BA.5 had comparable angiotensin-converting enzyme 2 (ACE2)-binding affinities to BA.2 [7]. Also, BA.2.12.1, BA.4, and BA.5 showed increased neutralization evasion compared with BA.2 when tested against plasma from patients with triple-vaccination and following infection with BA.1 [7]. Studies on epitope distribution and Omicron neutralization efficacy of neutralizing antibodies indicated that Omicron might evolve mutations to evade the humoral immune response following BA.1 infection [7]. Therefore, BA.1-derived vaccine boosters may not achieve adequate immune protection against the new Omicron lineages [7]. Laboratory studies have shown that antibodies generated following vaccination are less effective at blocking the BA.4 and BA.5 viruses than earlier Omicron variants, including BA.1 and BA.2, possibly due to L452R and F486V spike mutations in BA.4 and BA.5 [8]. Therefore, due to the increasing global transmission of the Omicron VOCs and the subsequent expected increased viral diversity, on 7 June 2022, the WHO added a new category to its SARS-CoV-2 variant tracking system [9]. The VOC Lineages Under Monitoring (VOC-LUM) initiative aims to inform global public health authorities of the VOC lineages that may require prioritized attention and monitoring (Table 2) [9]. The main objective of the VOC-LUM is to investigate whether these lineages pose an additional threat to global public health [9]. If any lineages show distinct characteristics that may increase disease incidence or severity compared to the original VOC, the TAG-VE and WHO may identify the virus as a VOC-LUM [9]. The B.1.1.529, or Omicron variant, of SARS-CoV-2 is currently the dominant variant circulating globally [9]. Some sublineages of Omicron show transmission advantage compared to other circulating VOC lineages and mutational changes that confer a transmission or infection advantage [9]. For example, some countries, including the UK, have made public health authorities aware that Omicron BA.2 may have a transmissibility advantage that explains its increasing prevalence, including in care homes [10]. The primary roles of the VOC-LUM initiative from the WHO include: a review of the global epidemiology of the viruses; tracking worldwide spread; sharing virus isolates via the WHO Biohub; submission of the complete genome sequences to a publicly available database; improving the understanding of any potential impacts of the VOC-LUM on the epidemiology of COVID-19; and laboratory assessments on the impact of the VOC-LUM on relevant virus characteristics [9].

Conclusions

The new WHO VOC-LUM initiative has been established to recognize the importance of new lineages and sublineages of the Omicron, or B.1.1.529, variant of SARS-CoV-2. The emergence of new lineages and sublineages of the Omicron, or B.1.1.529, variant of SARS-CoV-2, is likely to continue due to high mutation rates. The concern is that with reduced SARS-CoV-2 testing in populations, the epidemiological landscape of emerging viruses may become unclear due to the lack of viral genomic data.
  5 in total

1.  What Omicron's BA.4 and BA.5 variants mean for the pandemic.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2022-06       Impact factor: 49.962

2.  Omicron sub-lineage BA.2 may have "substantial growth advantage," UKHSA reports.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2022-01-31

3.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.

Authors:  Yunlong Cao; Ayijiang Yisimayi; Fanchong Jian; Weiliang Song; Tianhe Xiao; Lei Wang; Shuo Du; Jing Wang; Qianqian Li; Xiaosu Chen; Yuanling Yu; Peng Wang; Zhiying Zhang; Pulan Liu; Ran An; Xiaohua Hao; Yao Wang; Jing Wang; Rui Feng; Haiyan Sun; Lijuan Zhao; Wen Zhang; Dong Zhao; Jiang Zheng; Lingling Yu; Can Li; Na Zhang; Rui Wang; Xiao Niu; Sijie Yang; Xuetao Song; Yangyang Chai; Ye Hu; Yansong Shi; Linlin Zheng; Zhiqiang Li; Qingqing Gu; Fei Shao; Weijin Huang; Ronghua Jin; Zhongyang Shen; Youchun Wang; Xiangxi Wang; Junyu Xiao; Xiaoliang Sunney Xie
Journal:  Nature       Date:  2022-06-17       Impact factor: 69.504

4.  Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2.

Authors:  Dinah Parums
Journal:  Med Sci Monit       Date:  2021-06-21

5.  Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.

Authors:  Dinah V Parums
Journal:  Med Sci Monit       Date:  2022-02-01
  5 in total
  4 in total

1.  Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021-2022: A Naturalistic Case-Control Study in Sweden.

Authors:  Armin Spreco; Örjan Dahlström; Anna Jöud; Dennis Nordvall; Cecilia Fagerström; Eva Blomqvist; Fredrik Gustafsson; Jorma Hinkula; Thomas Schön; Toomas Timpka
Journal:  Vaccines (Basel)       Date:  2022-08-07

2.  Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses.

Authors:  Saverio Giuseppe Parisi; Carlo Mengoli; Monica Basso; Ilaria Vicenti; Francesca Gatti; Renzo Scaggiante; Lia Fiaschi; Federica Giammarino; Marco Iannetta; Vincenzo Malagnino; Daniela Zago; Filippo Dragoni; Maurizio Zazzi
Journal:  Vaccines (Basel)       Date:  2022-08-02

3.  The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health.

Authors:  Md Rabiul Islam; Mohammad Shahriar; Mohiuddin Ahmed Bhuiyan
Journal:  Health Sci Rep       Date:  2022-10-13

4.  Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.

Authors:  Delphine Planas; Isabelle Staropoli; Françoise Porot; Florence Guivel-Benhassine; Lynda Handala; Matthieu Prot; William-Henry Bolland; Julien Puech; Hélène Péré; David Veyer; Aymeric Sève; Etienne Simon-Lorière; Timothée Bruel; Thierry Prazuck; Karl Stefic; Laurent Hocqueloux; Olivier Schwartz
Journal:  Med (N Y)       Date:  2022-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.